H.C. Wainwright Downgrades Juniper Pharmaceuticals (JNP) to Neutral

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/8/2026

1. MRVL
2. ZS
3. STZ
4. PENG
5. NVDA
6. MSFT
7. SPY
8. SKYD
9. APLD
10. LEVI

Go back to H.C. Wainwright Downgrades Juniper Pharmaceuticals (JNP) to Neutral

Juniper Pharma (JNP) to Discontinue Development of COL-1077 After Phase 2b Trial Fails

August 17, 2016 5:27 PM EDT

Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) today announced that a recently completed Phase 2b clinical trial evaluating its 10% lidocaine bioadhesive vaginal gel, COL-1077, for the reduction of pain intensity in women undergoing an endometrial biopsy with tenaculum placement did not achieve its primary and secondary endpoints. The safety and pharmacokinetic (PK) profiles of COL-1077 were consistent with what has been observed in prior clinical trials of the lidocaine bioadhesive vaginal gel.

"We are disappointed that COL-1077 did not achieve the desired effect in this clinical trial. We believe the study was well-designed and -conducted,... More